Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem Cell Therapy Market 2020 Global Market Size, Analysis, Share, Research, Business Growth and Forecast to 2027 Coherent Market Insights – Bandera…

By Stell Cell Research

Coherent Market Insights published informative report on Global Stem Cell Therapy Market presents market size, historical breakdown data (20142019) and forecast (20202027). The report encompass insightful data on the main sectors of the global market. The report also evaluates the size, share, and growth rate of the businesses by conducting detailed analysis of the contribution of leading market players to the global industry.

The report emphasized competitive structure, segmentation, leading competitors, and industry environment. The report investigates Stem Cell Therapy market dynamics, including growth drivers, restraints, potential opportunities, threats, challenges, and other market trends.

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

Key players analyzed in the Stem Cell Therapy market study:

Osiris Therapeutics, Inc. Novartis AG, GlaxoSmithKline Plc., MEDIPOST Co., Ltd., Anterogen Co., Ltd. Pharmicell Co., Ltd. Holostem Terapie Avanzate S.r.l. JCR Pharmaceuticals Co., Ltd. NuVasive, Inc. RTI Surgical, Inc., and Fibrocell Science, Inc.

This Stem Cell Therapy report is very reliable as all the data and the information regarding the fnb industry is collected via genuine sources such as websites, journals, annual reports of the companies, and magazines. This global market research report is likely to show a considerable growth of market in percentage during the forecast period. Key insights of the report are complete and distinct analysis of the market drivers and restraints, major market players involved in this industry, detailed analysis of the market segmentation and competitive analysis of the key players involved.

Our competitor profiling includes evaluation of distribution channels and products and services offered by and financial performance of companies operating in the global Stem Cell Therapy market. We also provide Porters Five Forces, PESTLE, and SWOT analysis to assess competitive threat and examine other aspects of the global Stem Cell Therapy market. The report offers strategic recommendations, competitor benchmarking for performance measurement, and analysis of partnership, merger, and acquisition targets and industry best practices. It also provides analysis of profitability and cost across the industry value chain.

Competitive Rivalry-: The Stem Cell Therapy report incorporates the detailed analysis of the leading organizations and their thought process and what are the methodologies they are adopting to maintain their brand image in this market. The report aides the new bees to understand the level of competition that they need to fight for to strengthen their roots in this competitive market.

Principal Research:

The research team works with industry experts from the Global Stem Cell Therapy industry including the management organizations, processing organizations, value chain analytics by service providers of the Stem Cell Therapy market.

Subordinate Research:

In the Secondary research vital information about the Stem Cell Therapy industries value chain, total pool of key players, and application areas. Market separation is done as per the industrial drifts to the deepest level, terrestrial markets and key developments from both market place and technology-oriented viewpoints.

Various features and important queries have been answered in top-notch report

Competitors

In this section, various Stem Cell Therapy industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Sales and Revenue Analysis

Both, sales and revenue are studied for the different regions of the Stem Cell Therapy Market. Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions.

Market Dynamics

The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends in this section.

Application Usage

The section provides up-to-date information on the customer experience which can help identify the problems as well as detailed errors in the products. Through these findings, you will be able to provide solutions to it.

Why Purchase from Coherent Market Insights?

Data gathered by interviewing product development managers, CEOs, marketing executives, and other individuals affiliated to the Stem Cell Therapy market

Round the clock customer service to address client queries

Systematic, efficient, and result-oriented approach towards curating market reports

We offer business intelligence reports for a range of industrial verticals

Tailor-made reports available to fulfil the requirements of our clients

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

In this study, the years considered to estimate the market size of 2020-2027 Stem Cell TherapyMarket are as follows:History Year: 2014-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2027

Contact Us:Name: Mr.ShahPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.comVisit our Blog: https://hospitalhealthcareblog.wordpress.com/

Link:
Stem Cell Therapy Market 2020 Global Market Size, Analysis, Share, Research, Business Growth and Forecast to 2027 Coherent Market Insights - Bandera...

Increasing Demand of Cancer Stem Cell Therapy Market by 2020-2026 with Top Key Players like #VALUE! – News Times

By Stell Cell Research

Cancer Stem Cell Therapy Market research report has been published by A2Z Market Research to give desired insights to drive the growth of businesses. The report has been intelligently framed with the process of gathering and calculating numerical data regarding services and products. The report is inclusive of the prominent industry drivers and provides an accurate analysis of the key growth trends and market outlook in the years to come in addition to the competitive hierarchy of this sphere.

Get Sample copy of this Report @: http://www.a2zmarketresearch.com/sample?reportId=194432

Some of the Top Companies covered in this Report includes: AVIVA BioSciences, AdnaGen, Advanced Cell Diagnostics, Silicon Biosystems.

The global Cancer Stem Cell Therapy market is analyzed in terms of its competitive landscape. For this, the report encapsulates data on each of the key players in the market according to their current company profile, gross margins, sale price, sales revenue, sales volume, product specifications along with pictures, and the latest contact information. The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Cancer Stem Cell Therapy market in the near future.

The report summarized the high revenue that has been generated across locations like, North America, Japan, Europe, Asia, and India along with the facts and figures of Cancer Stem Cell Therapy market. It focuses on the major points, which are necessary to make positive impacts on the market policies, international transactions, speculation, and supply demand in the global market.

Global Cancer Stem Cell Therapy Market Detail Segmentation:

Segmentation by Type:

Segmentation by Application:

For More Information, [emailprotected]: http://www.a2zmarketresearch.com/enquiry?reportId=194432

Impressive insights of Global Cancer Stem Cell Therapy Market Research report:

Table of Contents

Global Cancer Stem Cell Therapy Market Research Report 2020 2026

Chapter 1 Cancer Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cancer Stem Cell Therapy Market Forecast

Buy Complete Report Only @ 2800 USD: http://www.a2zmarketresearch.com/buy?reportId=194432

If you have any special requirements, please let us know and we will offer you the report as you want.

Originally posted here:
Increasing Demand of Cancer Stem Cell Therapy Market by 2020-2026 with Top Key Players like #VALUE! - News Times

Stem Cell Antibody Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2026 – News Times

By Stell Cell Research

In the latest report on Stem Cell Antibody Market, added by UpMarketResearch.com, a concise analysis on the recent industry trends is covered. The report further includes statistics, market forecasts and revenue estimations that in addition highlights its status in the competitive domain as well as expansion trends adopted by major industry players.

The report is a detailed study on the Stem Cell Antibody Market with details regarding an in-depth assessment of the industry vertical. The evaluation is performed taking into consideration a dual perspective of consumption and production.

Request a sample Report of Stem Cell Antibody Market at: https://www.upmarketresearch.com/home/requested_sample/51767

Speaking of the production category, the report provides details regarding the product renumeration, manufacturing of the product and the gross margins of the firms manufacturing the products. With regards to the consumption, the study elaborates about the product consumption value and the product consumption volume along the status of import as well as export of the products.

A brief of the regional landscape:

Regional segmentation: North America, Europe, Asia Pacific, Middle East & Africa, Latin America.

What is the main objective of this section?

The report provides an overview of the regional segment of this industry.

Important details covered in the report:

An outline of the product spectrum:

Product segmentation:

Primary AntibodiesSecondary Antibodies

What is the main objective of this section?

The report provides an overview of the product reach.

Providing an overview of the report:

Data related to the application terrain:

Application segmentation:

ProteomicsDrug DevelopmentGenomics

What is the main objective of this section?

The study states details regarding the classification of the application spectrum.

Ask for Discount on Stem Cell Antibody Market Report at: https://www.upmarketresearch.com/home/request_for_discount/51767

Assessment of the application-based segment of the Stem Cell Antibody market:

An outline of the competitive reach:

Competitive segmentation:

Thermo Fisher Scientific Inc. (U.S.)Merck Group (Germany) Abcam plc (U.K.)Becton Dickinson and Company (U.S.)Bio-Rad Laboratories Inc. (U.S.)Cell Signaling Technology Inc. (U.S.)Agilent Technologies Inc. (U.S.)F. Hoffmann-La Roche Ltd (Switzerland)Danaher Corporation (U.S.)GenScript (U.S.) PerkinElmer Inc. (U.S.)Lonza (Switzerland) and BioLegend Inc. (U.S.)

What is the main objective of this section?

The report provides details regarding the competitive spectrum of the Stem Cell Antibody market.

Details from the report:

Information related to the growth margins of the firms, manufacturing expenses, renumeration and product costs are provided in the report.

The research report offers data related to the level to which the industry has been evaluated. Data with respect to analysis of the possibility of new investment projects undertaken as well as the research conclusions are inculcated in the report.

For More Information on this report, Request Inquiry At https://www.upmarketresearch.com/home/enquiry_before_buying/51767

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Stem Cell Antibody Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Purchase of This Report:https://www.upmarketresearch.com/buy/stem-cell-antibody-market

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

Read more:
Stem Cell Antibody Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2026 - News Times

Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders – Technology Networks

By Stell Cell Research

Technology Networksrecently had the pleasureof speaking with Bruce Steel, CEOEquillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.Bruce provides insight on the various indications the company is currently developing treatments for, elaborates on the clinical progress of their initial product candidate EQ001 (itolizumab), and explains the role CD6 plays in autoimmunity and how it can be targeted therapeutically.

Laura Lansdowne (LL): How can immunobiology be harnessed to develop therapeutics?Bruce Steel (BS): The role of the immune system is to defend the body against foreign organisms and cells, including cancerous cells, and in doing so, it must distinguish accurately between self- and non-self-entities a process called tolerance. Autoimmunity is an immune response directed against the bodys own healthy cells and tissues and is the underlying process in many inflammatory diseases. Autoimmunity results from a loss of tolerance caused in part by an imbalance in the relationship between effector T cells and regulatory T cells. Therefore, developing therapeutics, such as EQ001 (itolizumab), that target these critical regulators of immune activation pathways has the potential dramatically improve the lives of patients with severe autoimmune and inflammatory disorders.LL: What indications are you currently developing treatments for?BS: We select target indications based on three primary criteria: strong scientific rationale for why itolizumab has potential to be a best-in-class therapeutic approach, areas of high unmet medical need where there are little or no treatments available today, and indications where we believe there is an attractive future commercial opportunity. Today we have ongoing clinical trials with itolizumab in acute graft-versus-host disease (GVHD), uncontrolled asthma and lupus/lupus nephritis.

While these three indications are our initial areas of focus, we believe itolizumab has the potential to be developed in other areas such as transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders.We licensed itolizumab from our partner Biocon Limited who developed the drug and received regulatory approval in India for the treatment of psoriasis.LL: Can you tell us more about the mechanism of your drug candidate EQ001 (itolizumab)?BS: Itolizumab is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway, which plays a central role in modulating the activity and trafficking of effector T cells that drive a number of immune-inflammatory diseases.LL: What role does CD6 play in autoimmunity?BS: CD6 is a novel co-stimulatory receptor that uniquely modulates T cell activity and trafficking. It is a key checkpoint in regulating effector T cells that are central to autoimmune responses. CD6 binds activated leukocyte cell adhesion molecule (ALCAM). ALCAM is expressed on both antigen-presenting cells and tissue including the skin, gut, lung and kidney.In preclinical studies, blockade of CD6 with itolizumab leads to reduction in effector T cell activation and proliferation. Additionally, inhibiting the binding of ALCAM to CD6 with itolizumab modulates lymphocyte trafficking and reduces effector T cell infiltration into inflamed tissues.

Our work with CD6 builds upon the research conducted from researchers at the Dana-Farber Cancer Institute, our partner Biocon, and other leading academic centers. Today there are numerous peer reviewed publications related to the novel CD6 checkpoint receptor and targeting the CD6-ALCAM pathway.LL: Can you elaborate on the clinical progress of itolizumab?BS: Itolizumab is currently being studied in three different indications: acute graft-versus-host disease (aGVHD), uncontrolled moderate to severe asthma and lupus/lupus nephritis. This is an important catalyst year for Equillium as we expect initial data from all three programs in 2H 2020.

Each of these studies will allow us to understand the safety of itolizumab in these different disease areas and understand what potential dose we will carry forward. This is important as we consider making a larger investment in Phase II studies to advance the program.Bruce Steel was speaking with Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks.

Original post:
Exploiting Immunobiology To Treat Severe Autoimmune and Inflammatory Disorders - Technology Networks

Non Surgical Aesthetics Are in High Demand, So Thread Lifts Are a New Way to Achieve Instant Skin Tightening – Yahoo Finance

By Platelet Rich Plasma Injections

Painless non surgical skin tightening procedures are now available and very popular for people who don't want to go through surgery in order to look better. Call LifeGaines in Boca Raton for more information about "Thread Lifts."

Boca Raton, Florida--(Newsfile Corp. - March 5, 2020) - Thread Lifts are a simple, painless procedure used for skin tightening on the face, neck, or anywhere else on the body. As popular and effective as Botox is, it simply doesn't have the ability to lift the skin. In the past, there hasn't been a great way to produce lifting results without surgery.

Call LifeGaines to inquire about this new method of skin tightening in the South Florida area. Call 561-295-9007.

To view an enhanced version of this image, please visit:https://orders.newsfilecorp.com/files/6848/53186_lifegaines_orig.jpg

Non-surgical aesthetics are in high demand and ThreadLifts, new to the United States, have the ability to produce skin that is instantly lifted and tightened.

This procedure uses no cuts or incisions, only injections. Threads are needles that are pre-loaded with PDO thread. The whole needle is inserted in the tissue at the sub-dermal level, along the surface of the skin and then the needle is pulled out. Threads can be used nearly anywhere on the body, but they are especially effective on the neck and jawline.

What is PDO?

Polydioxanone (PDO) sutures have been used for surgical procedures for many decades. It is one of the safest materials to implant in the body. PDO is completely dissolvable and your skin fully absorbs it within 4 to 6 months, leaving no scar tissue behind. This is especially effective when it's used together with chemical peels, Botox, and fillers to effect a patient's entire facial structure, remove sunspots and other conditions.

It is a great way to rejuvenate and restore youthful contours to brows, cheeks, jowls and the neck area. They are also effective on the breasts, buttocks and upper arms, areas that are prone to sagging due to weight loss, aging, pregnancy and childbirth or poor muscle tone.

Story continues

Thread Lifts are a great way to rejuvenate and restore youthful contours to brows, cheeks, jowls and the neck area. Results from threads generally last between 12 months to several years depending on the area that has been treated, how many threads are used and what kinds of threads are used in each needle.

Amy Steffey, is a Licensed Nurse Practitioner with LifeGaines Medical and Aesthetics, and with Thread Liftsprocedure, she helps Boca Raton residents regain their confidence with rejuvenating procedures and body contouring.

Amy Steffey works at LifeGaines, which is one of the most highly respected Age Management Medical teams in South Florida. Age Management Medicine pioneer Dr. Richard Gaines is the founder of LifeGaines, and he has years of experience specializing in Hormone Replacement Therapy, Sexual Wellness, Platelet-rich Plasma, Stem Cells, Aesthetics, and Advanced Age Management protocols.

LifeGaines is located at 3785 N Federal Hwy #150, Boca Raton, FL 33431.

Call 561-295-9007 Today to Schedule a Consultation with Amy Steffey at LifeGaines Medical & Aesthetics Center in Boca Raton.

Related Images

people-who-dont-want-to-do-surgery.jpg People who don't want to do surgery could consider a non-surgical way of tightening skin. Call LifeGaines to inquire about this new method of skin tightening in the South Florida area. Call 561-295-9007.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53186

Go here to read the rest:
Non Surgical Aesthetics Are in High Demand, So Thread Lifts Are a New Way to Achieve Instant Skin Tightening - Yahoo Finance

Fiery Ragin’ Cajuns catcher Toro hot with his arm, bat – Daily Advertiser

By Platelet Rich Plasma Injections

Autoplay

Show Thumbnails

Show Captions

He didnt recruit him to UL, didnt sign him.

Before becoming head coach of the Ragin Cajuns last summer, in fact, Matt Deggs didnt really know much at all about catcher Sebastian Toro.

But Toro is Deggs kind of player, and after watching what hes done lately, its easy to understand why.

The kid just is a ball of energy. Hes so much fun to be around, Deggs said. His teammates love him. He loves to work. He loves to laugh.

Hes got a little flare to him, and Im drawn to that. I like guys that play with passion and flare, and play with confidence, and they want to drive the train and be the spark.

Hes got a lot of those qualities, Deggs added, and hes a great receiver, and he can really throw.

Can he ever.

More: Deggs looking for Cajuns to 'compete' at the plate

Ragin' Cajuns catcher Sebastian Toro celebrates on third base during a 1-0 win over Sam Houston State last Saturday at The Tigue.(Photo: James Mays/Special to the Advertiser)

Twice last weekend, actually, the redshirt junior from Bayamon, Puerto Rico, ended games a pair of victories over Sam Houston State, the team Deggs coached from 2015-19 with his arm.

And he did it after things didnt exactly go his, or the Cajuns, way on the first night of their three-game series with the Southland Conferences Bearkats.

On Friday, SHSU beat UL 5-4 in 11 innings.

In the top of the 11th the Cajuns intentionally walked Sam Houstons top two hitters, Jack Rogers and Colton Cowser, to load the bases before the Bearkats scored what proved to be the winning run when a wild pitch in the dirt from Connor Cooke got past Toro, who couldnt make the block.

Related: UL plan unravels in 11-inning loss to Sam Houston

But rather than keep him down, or make him gun-shy, Toro dusted himself off and bounced right back duringthe ninth inning of a 1-0 win the next day, one in which he singled and later scored UL's lone run.

First, with Cowser at the plate and the Cajuns clinging to their one-run lead, he popped up from behind the plate to pick off Anthony MacKenzie at first base for the second out of the inning, daring to make the same play he tried but failed in a game earlier in the season.

Then, with Rogers up after Cowser had walked, he gunned down Cowser at second to end it the first time in his career the U.S. Collegiate National Team member had been thrown out trying to steal.

Deggs called it a game-saving play, one that polished off pitcher Brandon Youngs three-hit, complete-game gem. Toro simply called itspecial.

A day later, with the series still undecided, Toro again threw out Cowser trying to steal second in the ninth, this time to preserve a 7-5 Cajuns victory and a 2-1 UL series win.

Special indeed.

No wonder teammates love him.

Toros amazing behind the plate, UL senior outfielder Gavin Bourgeois said. He has great energy, and hes really fun to watch.

Oh, and hes hitting a team-high .300 too heading into games Friday afternoon against Samford, Saturday afternoon against Michigan State and Sunday afternoon against Troy at Blue Wahoos Stadium in Pensacola, Florida.

Related: Toro keeps Sam Houston from stealing a thriller with UL

More: UL baseball defeats Sam Houston State 7-5

UL catcher Sebastian Toro talks to teammates during a game against Sam Houston State last Friday night on M.L. "Tigue" Moore Field at Russo Park.(Photo: James Mays/Special to the Advertiser)

Toro is a product of the Puerto Rico Baseball Academy and High School, a renowned program located not far from San Juan that has produced major-leaguers including Houston Astros shortstop Carlos Correa and Boston Red Sox catcher Christian Vasquez.

From there it was on to Seminole State College in Oklahoma, where Toro spent two seasons.

And last season, his first at UL, he got off to a strong start as a Cajun.

Toro was hitting .308 with six RBIs, and sharing time behind the plate with then-senior Handsome Monica had started seven of the 11 games in which he played.

More: Cajuns catcher Monica not ready to rest his case just yet

What's in a name?Monica wasn't born Handsome

In one early season outing against Maryland, he was 2-for-3 with two RBIs. In another against Loyola Marymount, he had two hits and scored a run.

But then his arm went sore.

Initially, late Cajuns coach Tony Robichaux who passed away last July, leading to the hiring of ex-UL assistant Deggs thought hed get Toro back before seasons end.

In time, though, it became apparent that wasnt going to happen. Toro wound up taking a medical redshirt instead.

It pained him to do so.

More: Bond is big for Deggs, Ragin' Cajun coaches still grieving

Related: Ragin' Cajuns unveil Robichaux statue 'just too soon'

It was frustrating, said Toro, who has had to overcome injury before.

My sophomore year (at Seminole) I broke my hand. But we were in the playoffs, so I didnt miss a lot of games. But last year it kind of hurt myself. I wasnt ready to play. My arm wasnt ready.

It kind of got me hard not playing, losing games, Toro added. Last year, I didnt do nothing to help my team win.

But that was 2019.

This is 2020, so Toro erased all memory of a year lost.

Its a new season, he said. You cant worry about what happened the last season.

But Toro didnt just think that.

The fiery, wide-smiling, charismatic Puerto Ricanlived it, and teammates could tell.

He really didnt complain at all when he had the injury, which is something pretty special, senior pitcher Young said. You know, a lot of guys kind of mope, kind of get down.

But he had his energy all the time, and its been paying off for him.

Has it ever.

More: Cajun arms getting it done as UL preps for road stretch

Related: Stacked UL pitching staff looks the part going into 2020

In 10 games played, nine of them starts, Toro already has thrown out 10 of 16 runners trying to steal.

He didnt have that kind of arm last year, Young said. Hes gotten a lot better.

Im surprised if he doesnt get his name called in the (MLB) Draft this year, for sure.

All this from someone whose arm, still on the mend in the fall, prevented Deggs from fully appreciating him early on.

UL's Sebastian Toro celebrates a double against Sam Houston State last Friday night at The Tigue.(Photo: James Mays/Special to the Advertiser)

Didnt know a lot about Sebastian coming in, because he was hurt, the first-season Cajuns coach said.

He hit a ball off the centerfield wall against us a year ago at Sam, and that was basically my experience with him.

But now?

I havent even heard about it or talked about it, Deggs, whose Cajuns are coming off Tuesday night's 11-2 win at Rice,said with reference to the arm injury. He just jumped in with both feet, and hes gone.

Related: Seven-run fifth pushes the Ragin' Cajuns past Rice

Its the new arm, though, that really has Toro going. That, and the bat, which has produced five RBIs and nine hits in 30 at-bats this year.

He didnt have surgery on the arm, but said he instead underwent PRP.

According to multiple medical websites, platelet-rich plasma therapy involves transfusion injections of a concentration of a patients own blood platelets to promote and accelerate the healing of damaged tendons, ligaments, muscles and joints.

I came out with a lot of confidence in myself right now, especially hitting too, said Toro, whose first language is Spanish.

Sometimes if I dont hit my confidence goes down, but I just try to be the same guy every day.

Its working.

During the middle game of a home series with Virginia Tech the weekend before the one with Sam Houston State, Toro struck out four times in row.

For the three-game series, he fanned six times in all and finished 2-for-11 at the plate.

Related: Cajuns strike out 16 times and 15 are stranded in loss to Virginia Tech

Toro knew he had to do something, anything, to shake the feeling.

So, for starters, he did what anyone else in his position would.

Just show up to the field, Toro said.

But before that he made a call.

I talked to my Dad (Anthony), Toro said.

I said, Hey, theres nothing I can do more. I just keep showing up, working hard, just try to get hits.

Reflective of the confidence he has in Toros bat, Deggs also did his part.

He had Toro hitting cleanup to open the SHSU series.

More: Alcohol cost Ragin' Cajuns baseball coach Matt Deggs, but Tony Robichaux saved him

Ragin' Cajuns catcher Sebastian Toro (center) is welcomed back to the dugout after scoring UL's lone run in a 1-0 win over Sam Houston State last Saturday.(Photo: James Mays/Special to the Advertiser)

When I saw that, Toro said, I was like, Man Im not used to hitting in the four-hole.

But I just used it as a challenge. I was gonna get there, get some pitches and try to get ahead and try to get in scoring position.

It worked.

Toro went 3-for-5 with a double and one run scored in ULs first game against Sam Houston, and he finished the series 4-for-8 with just two strikeouts, showing defense isnt the only reason hes a cut above.

The Cajuns carry three catchers, and all three have started at least once behind the plate this year.

But Toros play of late earned has earned him starts in four straight games and seven of 5-8 ULs last eight.

Its also prompted Deggs to find other places to play the Cajuns two reserve catchers so he can get their bats into the lineup too, prompting playtime at third base for junior backup Nick Hagedorn while Jonathan Windham deals with a hand injury and opportunity at first base for hot-hitting freshman Julian Brock.

More: Deggs' 2020 Cajuns loaded with 'interchangeable parts'

With the way he plays defensively, not to mention the bat, the Cajuns coach simply wants Toro in the lineup as long as he can hold up.

And why not?

The arm really is a weapon, a deterrent that could easily keep even the speediest of base-runners from trying to steal too much from the Cajuns.

He makes you extremely uncomfortable on the bases, Deggs said. It tightens up leads. Guys dont want to run as much, and its a definitive advantage.

Ragin' Cajuns catcher Sebastian Toro waits to tag out a Virginia Tech runner at the plate earlier this season at The Tigue.(Photo: James Mays/Special to the Advertiser)

Toros arm eases stress on Cajun pitchers too.

I dont have to make perfect pitches with a guy on first or second, at least, Young said. If I throw it a little out, (or) my timing can be a little off, and I know hes got me nine times out of 10 times.

Deggs understands well just how much that can lead to mind games in the opposite dugout.

Continued here:
Fiery Ragin' Cajuns catcher Toro hot with his arm, bat - Daily Advertiser

Study maps landmarks of peripheral artery disease to guide treatment development – University of Illinois News

By Gene Therapy Clinics

CHAMPAIGN, Ill. Novel biomedical advances that show promise in the lab often fall short in clinical trials. For researchers studying peripheral artery disease, this is made more difficult by a lack of standardized metrics for what recovery looks like. A new study from University of Illinois at Urbana-Champaign researchers identifies major landmarks of PAD recovery, creating signposts for researchers seeking to understand the disease and develop treatments.

Having these landmarks could aid in more optimal approaches to treatment, identifying what kind of treatment could work best for an individual patient and when it would be most effective, said Illinois bioengineering professor Wawrzyniec L. Dobrucki, who led the study. He also is affiliated with the Carle Illinois College of Medicine.

PAD is a narrowing of the arteries in the limbs, most commonly the legs, so they dont receive enough blood flow. It often isnt diagnosed until walking becomes painful, when the disease is already fairly advanced. Diabetes, obesity, smoking and age increase the risk for PAD and can mask the symptoms, making PAD difficult to diagnose. Once diagnosed, there is no standard treatment, and doctors may struggle to find the right approach for a patient or to tell whether a patient is improving, Dobrucki said.

The researchers used multiple imaging methods to create a holistic picture of the changes in muscle tissue, blood vessels and gene expression through four stages of recovery after mice had the arteries in their legs surgically narrowed to mimic the narrowing found in PAD patients. They published their results in the journal Theranostics.

There are a lot of people who study PAD, so there are all these potential new therapies, but we dont see them in the clinics, said postdoctoral researcher Jamila Hedhli, the first author of the paper. So the main goal of this paper is utilizing these landmarks to standardize our practice as researchers. How can we see if the benefit of certain therapies is really comparable if we are not measuring the same thing?

The cross-disiplinary collaboration identified landmarks over four stages of disease recovery. Pictured, from left: senior research scientist Iwona Dobrucka, professor Jefferson Chan, postdoctoral researcher Jamila Hedhli, graduate student Hailey Knox, professor Wawrzyniec Dobrucki, professor Michael Insana, adjunct John Cole.

Photo by Fred Zwicky

Edit embedded media in the Files Tab and re-insert as needed.

Dobruckis group collaborated with bioengineering professor Michael Insana, chemistry professor Jefferson Chan and senior research scientist Iwona Dobrucka, the director of the Molecular Imaging Laboratory in the Beckman Institute for Advanced Science and Technology, to monitor the mice with a suite of imaging technologies that could be found in hospitals or clinics, including ultrasound, laser speckle contrast, photoacoustics, PET and more. Each method documented a different aspect of the mouses response to the artery narrowing anatomy, metabolism, muscle function, the formation of new blood vessels, oxygen perfusion and genetic activity.

By serially imaging the mice over time, the researchers identified key features and events over four phases of recovery.

Each imaging method gives us a different aspect of the recovery of PAD that the other tools will not. So instead of looking at only one thing, now were looking at a whole spectrum of the recovery, Hedhli said. By looking at these landmarks, were allowing scientists to use them as a tool to say At this point, I should see this happening, and if we add this kind of therapy, there should be an enhancement in recovery.

Though mice are an imperfect model for human PAD, each of the imaging platforms the researchers used can translate to human PAD patients, as well as to other diseases, Dobrucki said. Next, the researchers plan to map the landmarks of PAD in larger animals often used in preclinical studies, such as pigs, and ultimately in human patients.

We are very interested in improving diagnosis and treatment, Hedhli said. Many people are working to develop early diagnosis and treatment options for patients. Having standard landmarks for researchers to refer to can facilitate all of these findings, move them forward to clinic and, we hope, result in successful clinical trials.

The National Institutes of Health, the American Heart Association, and the Ministry of Science and Higher Education of Poland supported this work. Chan, Dobrucki, Hedhli and Insana also are affiliated with the Beckman Institute. Hedhli was supported by a Beckman-Brown Postdoctoral Fellowship.

Excerpt from:
Study maps landmarks of peripheral artery disease to guide treatment development - University of Illinois News

Misophonia: A Neurologic, Psychologic, and Audiologic… : The Hearing Journal – LWW Journals

By Gene Therapy Clinics

iStock/nicoletaionescu, misophonia, pain, health.

Resources on Misphonia.

Misophonia1 is a newly described condition that is still not thoroughly understood. To her credit, Marsha Johnson, AuD, was the first to informally discuss sensitivity to specific sounds in online support groups for patients with hyperacusis, and documented about 500 cases of similar sound sensitivity problems in the late 1990s (personal communication, Dec. 3, 2019). She designed the term selective sound sensitivity syndrome (S4), which is still used today to describe misophonia. Later, Margaret Jasterboff, PhD, and Pawel Jastreboff, PhD, coined the term misophonia (which conservatively means dislike of sound),1,2 and other scientists such as Tyler, et al., refer to essentially the same condition as annoyance hyperacusis.3

Misophonia is considered sound intolerance and oversensitivity to certain sounds, which can result in distraction and annoyance that may limit a person's ability to concentrate, think, and learn.4 Some of the trigger sounds include gum popping, lip-smacking, food chewing or crunching, throat clearing, nose sniffing, breathing, tapping, and clicking.3, 5-8 Misophonia has yet to be classified in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); and unfortunately, the scientific community has not reached a consensus to categorize this condition as an auditory, psychiatric/psychologic, or neurologic ailment. This lack of recognition not only prevents health care providers from officially classifying the disorder but also hinders affected individuals from seeking help.

Misophonia can be associated with high levels of anxiety9 and comorbid factors, including post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and anorexia.10,11 Autonomous sensory meridian response (ASMR), usually triggered by auditory and visual stimuli, has been associated with heightened levels of misophonia. ASMR is described as a relaxing tingling sensation that starts from the head and neck and spreads through the body.12 Although sound sensitivity and hyperacusis have been investigated in autism spectrum disorder (ASD),13,14 misophonia has not been explored in children and adults with ASD. Misophonia can also cause academic difficulties. Connie Porcaro, PhD, a university professor, was concerned about misophonia awareness among her peers in the academic community. In 2019, she designed a study to see how much the university instructors knew about misophonia and what they would do to accommodate students with this condition in their classrooms. Of the 686 survey participants, only 18.4 percent self-reported having knowledge of misophonia. Instructors who knew about this condition indicated that they would be willing to provide classroom accommodations for those who suffer from misophonia.4

The neural correlates of misophonia have been explored, with areas of interest that include the non-classical auditory pathway, limbic system, and auditory cortices.7, 15-18 Kumar and colleagues employed fMRI in individuals with misophonia while they were exposed to unpleasant trigger sounds.16 The researchers found increased neuronal activities in an area referred to as the anterior insular cortex (AIC). Although the findings of this study have been questioned by some researchers,19 it still is considered as one of the strongest pieces of evidence for a neurological origin of misophonia. It is believed that AIC, in general, is a major player in emotional awareness,20 and one can simply expect the increased responses in this area in individuals with misophonia when they are exposed to trigger sounds. Schrder and colleagues provided additional evidence for a neurobiological basis for misophonia. They studied the response of the N1 component of late auditory evoked potentials to oddball stimuli in a group of subjects with misophonia. Their findings indicated a reduced amplitude in N1 to oddball stimuli. They concluded that a neurobiological deficit in those with misophonia could potentially impair auditory processing of incoming stimuli.18 Another fMRI study has shown some correlations between misophonia and OCD. fMRI data have indicated that those with misophonia have perfectionist and compulsive behaviors.21 These findings may support the clinical observation of annoyance at chewing sounds in those with misophonia.

Additionally, genetics may play a role in misophonia. Although no strong research supports a genetic basis of misophonia, Sanchez and Silva from Brazil have reported a family with 15 members with misophonia and a possible autosomal dominant inheritance.22 Anecdotally, some of our patients have reported a mutation in chromosome 5 when they checked their genetic makeup using commercially available kits. Interestingly, a gene by the name of TENM2, which is involved in brain development, has a cytogenic location at 5q34 (in chromosome 5, longarm region 3 band 4).23

No standard questionnaire has been developed for misophonia. During the evaluation, patients are usually asked to complete a set of surveys, such as the Misophonia Questionnaire,24 which has three subscales: the Misophonia Symptom Scale, Misophonia Emotions and Behaviors Scale, and Misophonia Severity Scale. Another useful tool is the Amsterdam Misophonia Scale (A-MISO-S),25 which is widely used in many clinics. There are no universally accepted protocols for misophonia evaluation. Dozier, et al., have proposed a set of diagnostic criteria for misophonia that employs a variety of misophonic stimuli, including both auditory and visual modalities.26 Some clinics may measure loudness discomfort levels, particularly if misophonia is associated with hyperacusis. Aazh and colleagues described the loudness level measures in a group of children and adolescents with tinnitus and hyperacusis, and noticed that the uncomfortable loudness levels (ULLs) were at least 20 dB lower at 8 kHz than at 250 Hz.27 These findings also provide important information on the assessment of misophonic triggers, such as high-pitched screeching, that are reported by some patients.

Misophonia can be managed through tinnitus retraining therapy (TRT), cognitive behavioral therapy (CBT), compassion training, distress tolerance, mindfulness, and acceptance-based treatment, among others.28 Comorbid conditions such as depression and anxiety could be treated with antidepressants and anxiolytics. Brout and colleagues recommended a multidisciplinary care pathway to develop coping skills through CBT, mindfulness, and behavioral change.29 In general, it is understood that mental health and comorbid factors such as anxiety and depression can exacerbate misophonic responses. Parental mental health has also been explored, and the effectiveness of treatment for sound sensitivity disorders has been shown to influence the treatment of people with a history of parental mental health illness.30, 31

TRT. TRT employs extensive counseling and sound therapy. In a study by Margaret and Pawel Jastreboff, on a relatively large number of patients with decreased sound tolerance disorders, 152 out of 184 patients with both misophonia and hyperacusis and 139 out of 167 patients with misophonia alone experienced improvements after TRT.32 In the clinical practice of Ali Danesh, PhD, the use of ear-level sound generators with pleasant signals such as Zen fractal music or other sounds streamed via a smartphone to a Bluetooth hearing device, combined with extensive counseling, were shown to be helpful in managing those with misophonia. However, no solid evidence-based data are available for this observation.

CBT. Since the models describing hyperacusis and tinnitus have significant commonalities with misophonia, it can be presumed that the methods used to treat tinnitus and hyperacusis can also be effective for misophonia. The evidence-based and research-proven protocols for hyperacusis and tinnitus management support CBT.33-35 The CBT protocol for misophonia is designed to identify negative automatic thoughts (NATs) and examine the validity and truth behind those negative thoughts. After a few sessions, patients realize that most NATs such as anger, isolation, fear, or poor relationships are false perceptions. Aazh and colleagues provide a case formulation model for a CBT plan to manage misophonia.36 This model starts with the exploration of misophonia patients initial emotional responses, such as anger and irritation, and their physical complaints, such as tightening of the stomach, static-like tingling sensations on the skin, or pain, when exposed to trigger sounds. These physical sensations and initial emotional reactions to trigger sounds generate a series of negative thoughts that lead to further emotional and physical responses, which in turn result in evaluative thoughts, hence generating a vicious circle of thoughts (Fig. 1).36 The CBT-based interventional model for misophonia aims to break this cycle by assisting the patients in examining and exploring their negative thoughts so they can process and modify them.

Although there is no quick fix or magic pill for misophonia, the use of sound therapies, behavioral modifications, and CBT seems to be promising. Further research will be able to show the effectiveness of other treatment methods, such as electrical and magnetic stimulations, in the search for misophonia management.

More:
Misophonia: A Neurologic, Psychologic, and Audiologic... : The Hearing Journal - LWW Journals

‘His legacy lives on’: Grandmother who helped create newborn screening law tells history of bill – News-Leader

By Stem Cell Doctors

Buy Photo

Two-year-old Regann Moore lights up as she watches videos on her iPad at home on Thursday, Feb. 20, 2020. Moore has a rare disease known as Krabbe Disease and received a life-saving stem cell donation less than a month after being born.(Photo: Nathan Papes/Springfield News-Leader)

Soon after the News-Leader published a story about 2-year-old Regann Moore,a Springfield child whose life was saved thanks to a newborn screening test, someone tweeted the story toMissouri State Rep. Becky Ruth.

"I bawled my eyes out," Ruth said. "I just cried."

She cried because she knew Regann is alive thanks to the death of Ruth's grandson, Brady.

"I cry and smile when I see these children," Ruth said. "We are always so thankful. For us, we see Brady's death wasn't in vain. His legacy lives on by helping save the lives of other children."

More: Springfield child with rare, deadly disease continues to amaze doctors, family

Regann, who is 2 now, was diagnosed right after she was born withKrabbe Disease, a rare metabolic disorder that must be diagnosed at birth and treated as soon as possible with a stem cell donation.

The newborn screening is important because babies with Krabbe Disease appear healthy at birth. Signs something is wrong usually don't appear until it's too late for treatment to be effective.

That is what happened to Brady in 2009. He wasn't diagnosed with the disease until he was 4.5 months old too late for treatment.

Brady died 10 days before his first birthday.

Brady Cunningham died of Krabbe Disease just before his first birthday.(Photo: Courtesy of the Cunningham family)

That's why Ruth and her family fought to get lawmakers on board with making sure all newborns in Missouri are screened for Krabbe Disease.

TheBrady Alan Cunningham Newborn Screening Act was passed in 2009 and screening began in 2012. Ruthsaid her family was OK with the three-year lag because they realized the lab needed time to become equipped to test for the disease.

Missouri is one of just a few states that do the newborn screening.

Brady's law also includes screening for Pompe, Fabry, Gauche and Niemann-Pick diseases. Since then, SCID, MPS I, MPS II and SMA diseases are screened, as well.

Ruth became a state representative in 2015and said newborn screening is her passion.

Her experience with getting Brady's law passed is what led her to seek office.

"It showed me what just a regular everyday person can do and what a differenceyou can make," Ruth said. "People a lot of times complain about politicians and the legislature, but we also do very good things here."

Ruth said her family knows of another child with Krabbe Disease who was saved thanks to newborn screening and a stem cell transplant.

That child is now 4. Ruth said her family and that child's family have a "strong connection."Ruth said shehopes to someday meet Regann's family.

Brady Cunningham was born in 2008. His family is from Campbell in southeast Missouri.

Bradyappeared healthy at birth and was not tested for Krabbe Disease.

Ruth said he started having health problems after about a month and a half. Brady went through "a myriad of diagnoses," Ruth recalled, including acid reflux and seizures.

"Finally my daughter took him to Children's Hospital in St. Louis," she said. "They promised her he wouldn't leave without a diagnosis."

Missouri State Rep. Becky Ruth was moved to tears after reading about Regann Moore, a Springfield child whose life was saved thanks to newborn screening for Krabbe Disease. Ruth and her family encouraged Missouri lawmakers to make sure all Missouri babies are tested for the deadly disease after her grandson, Brady, died from it.(Photo: Submitted by Becky Ruth)

Three weeks later, Brady was diagnosed with Krabbe Disease, which rapidly destroys the nervous system.

"We were told there was nothing they could do," she said. "It was one of the worst days of all of our lives."

Brady was 4.5 months old when he was diagnosed. In order for a stem cell donation to have any chance of being effective, babies must have the transplant within the first month of their life.

Regann, the Springfield child, was given a stem cell donation thanks to an umbilical cord donation.

Thediseaseaffects about one in every 100,000 people in the United States.

"They are missing an enzyme that helps keep their nervous system intact," said Dr. Shalini Shenoy, Regann's transplant doctor. "Because this is missing, they have degeneration of the brain and nervous system. And if you let it progress, it is fatal very early."

Without the stem cell donation, babies die within the first few months, Shenoy said.

"You can't change someone's genetic makeup," Shenoy said. "But when you put stem cells into their bone marrow from somebody else who is normal, some of these cells migrate into their brain and into their nervous system and supply what they are lacking themselves."

It takes some time for the transplant to begin working for the transplanted cells to "settle down" and begin making the missing enzyme, Shenoy said.

"Because of that, the earlier you transplant a Krabbe patient, the more you will be able to rescue them," she said. "You want to catch them before too much damage is done. Once there's a lot of nerve damage, it's not reversible. If I saw a Krabbe patient two months after they were born or four months after they were born when they already had major problems, it's unlikely I'd be able to rescue them too much."

Since the screening and the stem cell transplant treatment are both relatively recent medical advancements, Shenoy said it's anybody's guess what the future will hold for children who, like Regann, were successfully treated with a stem cell transplant early on.

Ferrell Moore holds his two-year-old daughter Regann Moore at their home on Thursday, Feb. 20, 2020. Regann has a rare disease known as Krabbe Disease and received a life-saving stem cell donation less than a month after being born.(Photo: Nathan Papes/Springfield News-Leader)

Regann can't stand on her own or walk yet. But her family is determined to make that happen. She cannot talk but is learning sign language to communicate.

She has regular visits with speech and occupational therapists.

Regann's dad Ferrell Moore got to take her to the circus recently, something the little girl seemed to enjoy.

"She is the joy of my life," Ferrell Moore said. "When I come home, it couldn't be any better to see her and how happy she is to see me."

Read or Share this story: https://www.news-leader.com/story/news/local/ozarks/2020/03/05/grandma-who-helped-pass-newborn-screening-law-tells-story-bill/4954655002/

Excerpt from:
'His legacy lives on': Grandmother who helped create newborn screening law tells history of bill - News-Leader

In Maine, Tougher Vaccine Rules Were On Super Tuesday Ballot : Shots – Health News – NPR

By Stem Cell Doctors

Pediatrician Laura Blaisdell, co-chair of Maine Families for Vaccines, joined supporters at the Augusta State House in February for a campaign event. Patty Wight/Maine Public Radio hide caption

Pediatrician Laura Blaisdell, co-chair of Maine Families for Vaccines, joined supporters at the Augusta State House in February for a campaign event.

Voters in Maine upheld a new state law that eliminates philosophical and religious exemptions for mandated childhood vaccines. A statewide referendum on Tuesday's ballot asked whether voters wanted to overturn the law that eliminates religious and philosophical exemptions for childhood vaccines. Bangor Daily News called the results with more than half of precincts reporting: 71.5% voted against overturning the new vaccine law.

Molly Frost of Newcastle wanted the new law to remain in place. Her 11-year-old son, Asa, has a compromised immune system. He was diagnosed with Hodgkin's lymphoma, a type of cancer, when he was 5 and has relapsed three times. Frost says Asa has undergone several rounds of chemotherapy, radiation and, most recently, a stem cell transplant.

"He, at this point, has no immunity against any of the things he was vaccinated for in the past and could get very sick from those diseases were he to catch them," she says.

Cancer and treatment for it make Molly Frost's 11-year-old son Asa, reliant on "herd immunity" among his classmates and community to avoid pertussis and measles. Patty Wight/Maine Public Radio hide caption

Cancer and treatment for it make Molly Frost's 11-year-old son Asa, reliant on "herd immunity" among his classmates and community to avoid pertussis and measles.

That worries Frost, especially because her family lives in a coastal county where vaccine exemption rates are at least 9 percent one of the highest rates in the state. She was glad when the Maine Legislature passed the law last year intended to protect kids like her son. It aims to boost immunization rates of kids entering school by eliminating non-medical exemptions. The law will go into effect Sept. 1, 2021.

"It's a huge infringement on personal freedoms," says Cara Sacks, co-chair of the group that put the repeal on the ballot, "on medical freedom in particular."

The group was hoping to repeal any ban on non-medical exemptions and includes parents like Angie Kenney who wanted to keep the philosophical exemption for vaccines. Kenney has used the philosophical exemption to refuse immunizations for her kids ever since her older daughter had an adverse reaction after receiving the chicken pox vaccine at 18 months old.

"She could not crawl," Kenney says. "She couldn't walk. She couldn't even feed herself. And this went on for almost a year."

Her daughter was diagnosed with a brain injury called ataxia. It's listed by the Centers for Disease Control and Prevention as an adverse event that's known to occur extremely rarely after chicken pox vaccination; Kenney says she received a payment from the National Vaccine Injury Compensation Program. Her daughter has recovered and is now a teenager. But Kenney also has a 4-year-old and doesn't think the state should force her to get either girl vaccinated. "I am not sacrificing my child for the greater good of the community," she says.

Across Maine, though, physicians and health organizations say the new law is urgently needed to protect public health because more and more parents are using exemptions.

Cara Sacks, campaign manager of the Yes on 1 campaign, stands with supporters at a press conference last month at the State House in Augusta, Maine. Patty Wight/Maine Public Radio hide caption

Cara Sacks, campaign manager of the Yes on 1 campaign, stands with supporters at a press conference last month at the State House in Augusta, Maine.

More than 5% of kindergartners in Maine now have non-medical exemptions more than double the national average.

That has pushed vaccination rates for many diseases below 95% the critical threshold to achieve "herd immunity" within a community and thereby avoid spreading a disease to kids who, like Asa Frost, have compromised immune systems.

Pediatrician Dr. Laura Blaisdell says she has daily conversations with parents about vaccines but has felt helpless in recent years as she has witnessed immunization rates drop in Maine.

"We have gotten to a point where there are no other solutions," says Blaisdell of the new law eliminating non-medical exemptions. She is now the spokeswoman for the group which fought the repeal effort.

Maine has the nation's second-highest rate of pertussis, a vaccine-preventable disease that's also known as whooping cough.

Blaisdell is also worried about measles. If other states have an outbreak of that highly contagious disease, she says, it could easily travel to Maine through the millions of tourists who visit the state each summer.

"That sort of traffic is exactly the sort of traffic that diseases like measles would just love," she says.

More than $1 million was spent on the referendum battle. The campaign to preserve Maine's new law received its initial support largely from doctors, nurses and health organizations. In the latest campaign filings, the group got a $500,000 boost from the pharmaceutical companies Pfizer and Merck. The trade group Biotechnology Innovation Organization, which represents the biotech industry, also contributed $98,000.

Meanwhile, the campaign to repeal the law, Yes on 1, adopted "Reject Big Pharma" as its primary slogan.

That campaign received much of its early support from individual donations and chiropractors. More recently, the Organic Consumers Association contributed $50,000. The Minnesota-based group has been criticized for stoking vaccine fears and contributing to a measles outbreak in the state's Somali community three years ago.

The backlash that has erupted over Maine's new law doesn't surprise Alison Buttenheim, an associate professor at the University of Pennsylvania. She studies vaccine hesitancy and state exemptions. When states eliminate entire categories of exemptions, she says, some people perceive that as parental rights being sacrificed for public health.

"You sort of wonder, could Maine have taken a different policy step?" Buttenheim says. "Maybe, [by] making those exemptions harder to get, [the state could have] accomplished the same goal of coverage and disease protection without having to go through a big repeal effort."

With the new law preserved Maine joins four other states that don't allow any non-medical exemptions for vaccinations.

This story is part of NPR's reporting partnership with Maine Public Radio and Kaiser Health News.

View post:
In Maine, Tougher Vaccine Rules Were On Super Tuesday Ballot : Shots - Health News - NPR

→←